Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Eric who wrote (1429768)	12/20/2023 9:34:03 PM
From: Broken_Clock	2 Recommendations Recommended By Bill longz Read Replies (1) \| Respond to of 1571895

Once again you're flat out lying. Ivermectin was introduced to animals in 1981, the same year testing began with humans. It was designed originally for veterinary use only on animals. Ivermectin: a multifaceted drug of Nobel prize-honoured distinction ... In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world's most devastating tropical diseases. Discovery of Ivermectin - American Chemical Society In the late 1960s and early 1970s, Satoshi Omura (*1935), a microbiolo-gist and bioorganic chemist at Tokyo's Kitasato Institute, hunted for new sources of pharmaceuticals. He knew that some existing drugs, includ-ing antibiotics, had been derived from compounds found in nature. These gratifying results led Merck to commercialize ivermectin as a veterinary treatment beginning in 1981. Starting in 1987, the drug was also marketed to the public under the brand name Heartgard® (now sold by the animal-health company Me- rial) to prevent heartworms in dogs. These products quickly became the top-selling veterinary medicines in the world, with sales topping $1 billion annually. At Campbell’s urging, his colleagues studied ivermectin as a potential treatment for river blindness. Ivermectin is a particularly attrac- tive treatment because it has no antibacterial or antiviral activity, and has few serious side effects. Researchers discovered that’s because these drugs act primarily on cellular channels of the target organism that are not accessible in people, pets or livestock. In young worms, the drug alters the function of these channels in nerve and muscle cells, leading to paralysis. In addition, the drug makes these imma- ture worms more vulnerable to the human immune response, and stops adult female worms from releasing larvae. This combined effect helps end the parasite infestation. In its drug development efforts, Merck worked with the World Health Organization (WHO) to design and implement human clinical trials with ivermectin for river blind- ness in Senegal in 1981, under the direction of physician Mohammed Aziz (1929–1987). The results with single doses of the pill proved the effectiveness of the drug against river blind- ness, and ivermectin was approved for human use in 1987 under the name Mectizan®.